Cargando…
Current and future applications of the anti-IgE antibody omalizumab
IgE antibodies are a pivotal factor in pathophysiology of allergic diseases, and the possibility of reducing their level by anti-IgE has long been envisioned. Following several attempts, an effective biologic agent was obtained with the recombinant humanized mono-clonal antibody (rhuMAb)-E25, known...
Autores principales: | Incorvaia, Cristoforo, Mauro, Marina, Riario-Sforza, Gian Galeazzo, Frati, Franco, Tarantini, Francesco, Caserini, Maurizio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727776/ https://www.ncbi.nlm.nih.gov/pubmed/19707429 |
Ejemplares similares
-
IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future
por: Incorvaia, Cristoforo, et al.
Publicado: (2017) -
Omalizumab, an anti-immunoglobulin E antibody: state of the art
por: Incorvaia, Cristoforo, et al.
Publicado: (2014) -
Sublingual immunotherapy in allergic asthma: Current evidence and needs to meet
por: Incorvaia, Cristoforo, et al.
Publicado: (2010) -
Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium
por: Incorvaia, Cristoforo, et al.
Publicado: (2008) -
About the effect of pulmonary rehabilitation on lung function in patients with chronic obstructive pulmonary disease
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)